Amendments to the Claims

27. (cancelled).

28. (cancelled).

29. (cancelled).

30. (cancelled).

31. (cancelled).

32. (cancelled).

33. (cancelled).

34. (amended) A shelf-stable solution formulation comprising a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) molecule, wherein the molecule comprises the same amino acid sequence as a molecule selected from the group consisting of GLP-1(7-34), GLP-1(7-35), GLP-1(7-36), GLP-1(7-37), or the amide forms thereof, ~~comprising~~ and at least one modification selected from the group consisting of:

(a) substitution of a glycine, serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, phenylalanine, arginine, or D-lysine for lysine at position 26 and/or position 34 or substitution of a glycine, serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, phenylalanine, lysine, or a D-arginine for arginine at position 36;

(b) substitution of an oxidation-resistant amino acid for tryptophan at position 31;

(c) substitution of at least one of: tyrosine for valine at position 16; lysine for serine at position 18; aspartic acid for glutamic acid at position 21; serine for glycine at position 22; arginine for glutamine at position 23; arginine for alanine at position 24; and glutanine for lysine at position 26; and

(d) substitution comprising at least one of: glycine, serine, or cysteine for alanine at position 8; aspartic acid, glycine, serine, cysteine, threonine,

asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, or phenylalanine for glutamic acid at position 9; serine, cysteine, threonine, asparagine, glutamine, tyrosine, alanine, valine, isoleucine, leucine, methionine, or phenylalanine for glycine at position 10; and glutamic acid for aspartic acid at position 15;

a pharmaceutically acceptable preservative; and a tonicity modifier, wherein said formulation has a pH that is about 8.2 to about 8.8.

35. (cancelled)

36. (amended) The formulation of claim 34, wherein ~~the GLP-1 molecule is selected from the group consisting of GLP-1(7-34), GLP-1(7-35), GLP-1(7-36), GLP-1(7-37), or the amide forms thereof, and provided that~~ arginine is substituted for lysine at position 34.

37. (previously presented) The formulation of claim 34 wherein the formulation is buffered by TRIS.

38. (cancelled)

39. (cancelled)

40. (previously presented) A method for treating diabetes comprising administering to a patient in need of such treatment an effective amount of the formulation of claim 34.

41. (previously presented) A shelf-stable solution formulation comprising a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) molecule which comprises the amino acid sequence:

R_1-X-Glu-Gly^{10}-Thr-Phe-Thr-Ser-Asp^{15}-Val-Ser-Ser-Tyr-Leu^{20}-Y-Gly-Gln-Ala-Ala^{25}-Lys-Z-Phe-Ile-Ala^{30}-Trp-Leu-Val-Lys-Gly^{35}-Arg-R_2 (SEQ ID NO:2)

wherein R_1 is His or desamino-histidine, X is Ala, Gly or Val, Y is Glu or Gln, Z is Glu or Gln and R_2 is Gly-OH;

a pharmaceutically acceptable preservative; and a tonicity modifier, wherein said formulation has a pH that is about 8.2 to about 8.8.

42. (cancelled)

43. (previously presented) The formulation of claim 41, wherein R_1 is L-histidine, X is Val, Y is Glu, Z is Glu, and R_2 is Gly-OH.

44. (previously presented) The formulation of claim 41 wherein the formulation is buffered by TRIS.

45. (cancelled)

46. (cancelled)

47. (previously presented) A method for treating diabetes comprising administering to a patient in need of such treatment an effective amount of the formulation of claim 41.